

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph that appears from page 30, line 18 through page 31, line 3 with the following replacement paragraph:

Diagnostic kits for carrying out the methods disclosed above are also provided by the invention. Such kits comprise at least one detectable reagent that binds to IRS-1 and/or IRS-2 when phosphorylated at Ser1101 and/or Ser1149, respectively. In a preferred embodiment, the reagent is an IRS-1/2 antibody of the invention. In one embodiment, the invention provides a kit for the detection of phosphorylated IRS-1 (Ser1101) and/or IRS-2 (Ser1149) in a biological sample comprising (a) at least one IRS-1/2 antibody of the invention (e.g., a phospho-specific antibody that binds phospho-IRS-1/2 (Ser1101/Ser1149)) and (b) at least one secondary antibody conjugated to a detectable group. The reagents may also include ancillary agents such as buffering agents and protein stabilizing agents, e.g., polysaccharides and the like. The diagnostic kit may further include, where necessary, other members of the signal-producing system of which system the detectable group is a member (e.g., enzyme substrates), agents for reducing background interference in a test, control reagents, apparatus for conducting a test, and the like.

Please replace the paragraph that appears from page 31, lines 4-12 with the following replacement paragraph:

In another embodiment, the invention provides a kit for the detection of PKC theta activity in a biological sample comprising (a) at least one IRS-1/2 antibody of the invention (e.g., a phospho-specific antibody that binds phospho-IRS-1 (Ser1101) and/or phospho-IRS-2 (Ser1149)) and (b) at least one secondary antibody conjugated to a detectable group. Ancillary agents as described above may likewise be included. The test kit may be packaged in any suitable manner, typically with all elements in a single container along with a sheet of printed instructions for carrying out the test.